MedTrace Logo

The Effect of Long-term Daily Stimulation of the Brain With Pulsed Electromagnetic Fields on Parkinsons Disease

NCT07306104 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-04-29

No results posted yet for this study

Summary

The goal of this clinical trial is to learn to what extent daily stimulation of the brain with transcranial pulsed electromagnetic fields (T-PEMF) works to treat persons with Parkinson's Disease. The main questions it aims to answer are:

* How does 6 months of daily treatment (30 minutes/day) with T-PEMF affects neuro-mechanical and molecular biological factors compared with placebo treatment in persons with Parkinson's disease?
* How does 12 months of daily treatment (30 minutes/day) with T-PEMF affects neuro-mechanical and molecular biological factors in persons with Parkinson's disease an does 12 months of T-PEMF alters the need for medication intake?

The neuro-mechanical outcomes are compared with the "natural" progression of the disease as well as with a healthy reference group. Furthermore, it will be examined whether 12 months of T-PEMF treatment alters the need for medication intake.

Participants in the intervention group will:

* receive one 30 min treatment session daily for 12 months
* receive either T-PEMF or sham treatment for the first 6 months
* receive active T-PEMF treatment the last 6 months
* visit for tests before treatment initiation, after 6 months of treatment and after 12 months of treatment.

Conditions

  • PARKINSON DISEASE (Disorder)

Interventions

DEVICE

Transcranial pulsed electromagnetic fields (T-PEMF)

30 min daily stimulation with transcranial pulsed electromagnetic fields (50 Hz)

DEVICE

Sham (No Treatment)

30 min daily the participants are using/wearing the T-PEMF device but no stimulation occurs

Sponsors & Collaborators

  • Odense University Hospital

    collaborator OTHER

  • Bente & Erik Schøller Larsens Foundation

    collaborator UNKNOWN

  • University of Southern Denmark

    lead OTHER

Principal Investigators

  • Anne Sofie Bøgh Malling, Ph.d. · University of Southern Denmark

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-02-16
Primary Completion
2028-01-31
Completion
2028-01-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07306104 on ClinicalTrials.gov